Abstract:In Crohn's disease, the mucus layer appears to be defective in terms of low defensin levels and lack of antibacterial activity. These deficiencies actually explain the Montreal phenotypes and the stable localization of disease in the terminal ileum with low α-defensins from Paneth cells and/or low β-defensins in colonic disease, respectively. Conversely, in ulcerative colitis (UC) the defensin production is normal or even induced, but the mucus layer is thinner and patchy, more in the liquid form and also chemically altered so that antibacterial peptides are not retained and lost into the luminal bacterial bulk. Therefore, both barrier problems allow slow bacterial attachment and invasion, ultimately triggering the massive response of adaptive immunity and tissue destruction. Therefore, leakiness should refer to the antibacterial barrier and not to the general barrier against small molecules, such as mannitol or lactulose, which are not antigenic. The most promising approach in UC seems to be the use of probiotics or the natural compound lecithin as a stabilizer of mucus structure to enhance the barrier. While a phase II study has yielded positive results, the results of the ongoing phase III study are eagerly awaited. It is quite possible that the protective effect of smoking in UC is related to mucus production in the colon also, but this is not an option. Another alternative would be to shift cell differentiation in the colon towards goblet cell; the relevant differentiation factors are known. In Crohn's disease, the direct oral application of defensins might be effective if release and binding to the mucus are achieved. In the experimental colitis model, this works quite well. In conclusion, in a situation where enthusiasm about so-called biologics is declining due to loss of response over time, searching for the primary defects in inflammatory bowel disease and treating them may well be worthwhile, although it is unlikely to provide rapid relief.

Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Research progress on intestinal mucosal barrier and probiotics

Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy

Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease

Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis

Modified montmorillonite armed probiotics with enhanced on-site mucus-depleted intestinal colonization and H2S scavenging for colitis treatment

Modified Montmorillonite Armed Probiotics with Enhanced On-Site Mucus-Depleted Intestinal Colonization and H2S 2 S Scavenging for Colitis Treatment

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

Improvement of a 'Leaky' Intestinal Barrier

The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives

Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases

Molecular regulation of the intestinal epithelial barrier: implication in human diseases.

Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease

Puerarin Rebuilding the Mucus Layer and Regulating Mucin-Utilizing Bacteria to Relieve Ulcerative Colitis

Reinforcement of the intestinal mucosal barrier via mucus-penetrating PEGylated bacteria

Postbiotic muramyl dipeptide alleviates colitis via activating autophagy in intestinal epithelial cells

Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis

Intestinal Mucosal Barrier Improvement with Prebiotics: Histological Evaluation of Longish Glucomannan Hydrolysates-Induced Innate T Lymphocyte Activities in Mice

The potential of Akkermansia muciniphila in inflammatory bowel disease